Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
about
Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis.Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis.Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review.
P2860
Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Vedolizumab for the Treatment ...... E Single Technology Appraisal.
@en
type
label
Vedolizumab for the Treatment ...... E Single Technology Appraisal.
@en
prefLabel
Vedolizumab for the Treatment ...... E Single Technology Appraisal.
@en
P2093
P2860
P50
P1433
P1476
Vedolizumab for the Treatment ...... CE Single Technology Appraisal
@en
P2093
Alice Bessey
Paul Tappenden
Sami Hoque
P2860
P2888
P304
P356
10.1007/S40273-015-0334-3
P577
2016-03-01T00:00:00Z